USO DE EMPAGLIFLOZINA NO TRATAMENTO DA SÍNDROME DA SECREÇÃO INAPROPRIADA DO HORMÔNIO ANTIDIURÉTICO: UMA REVISÃO NARRATIVA DA LITERATURA

Abstract

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a disease characterized by an imbalance between sodium and water that leads to euvolemic hyponatremia. First described in 1957, the disease remains without a therapeutic basis with robust evidence to this day. In this context, empagliflozin, a representative of the SGLT2 inhibitors, emerges as a therapeutic perspective for the treatment of this condition. The objective of the present study is to analyze the therapeutic perspectives of the syndrome of inappropriate antidiuretic hormone secretion, emphasizing the use of empagliflozin, through a literature review. This study was made based on a narrative review of the literature, through research in bibliographic sources at the National Library of Medicine (NIH), from which articles from the PUBMED database were used, using the descriptors “empagliflozin” and “SIADH” combined by the Boolean operator “AND”. 04 articles were used after reading the abstracts that met the proposed criteria, with the selected articles being read in full.There are relatively few clinical trials and a small sample size on the use of empagliflozin in the treatment of SIADH. Therefore, although the initial results are promising, more studies are needed to elucidate the benefits and potential risks of the proposed new treatment.